



Pharmaceuticals —

Pipeline Overview and Progress

October 30, 2025 —
Investor Relations



Phase III	
Darolutamide (AR Inhibitor) // Adjuvant Prostate Cancer (DASL-HiCaP) // Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)	
Sevabertinib (HER2/mEGFR Inhibitor) // Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)	
Finerenone (MR Antagonist) // Non-diabetic Chronic Kidney Disease (FIND-CKD) // Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)	
Vericiguat (sGC Stimulator) // Heart Failure (HFREF) (VICTOR ²)	
Asundexian (FXIa Inhibitor) // 2 ^o Stroke Prevention (OCEANIC-STROKE)	
Bemdaneprocel (Cell Therapy) // Parkinson's Disease (exPDite-2)	


 Oncology
 Cardiovascular+³
 Neurology & Rare Diseases
 Immunology
 Others

 New molecular entity
 Life cycle management





Pharmaceuticals – Pipeline Details Oncology¹ (as of October 30, 2025)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Darolutamide (AR Inhibitor)	Adjuvant Prostate Cancer (DASL-HiCaP)					NCT04136353	Q1 2028	Study ongoing
	Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)					NCT05794906	Q3 2027	Study ongoing
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)	Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)					NCT06452277	Q2 2027	Study ongoing
	Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)					NCT06760819	Q1 2027	Study ongoing
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)	Advanced Solid Tumors					NCT05954312	Q4 2027	Study ongoing
225Ac-Pelgifatamab (BAY 3546828)	Advanced Prostate Cancer					NCT06052306	Q2 2027	Study ongoing
225Ac-PSMA-Trillium (BAY 3563254)	Advanced Prostate Cancer					NCT06217822	Q2 2027	Study ongoing
SOS1 Inhibitor (BAY 3498264)	Advanced Solid Cancers					NCT06659341	Q3 2027	Study ongoing
PRMT5 Inhibitor (BAY 3713372)	MTAP-deleted Solid Tumors					NCT06914128	Q2 2029	Study ongoing
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)	Advanced Solid Tumors					NCT06804824	Q3 2027	Study ongoing
225Ac-GPC3 (BAY 3547926)	Advanced Liver Cancer					NCT06764316	Q3 2030	Study ongoing
VVD WRN Inhibitor (VVD-214)	Advanced Solid Tumors					NCT06004245	Q2 2027	Study ongoing
KRAS G12D Inhibitor (BAY 3771249)	Advanced Solid Tumors					NCT07207707	Q3 2026	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit

³ *Bayer acquired Noria and PSMA Therapeutics in 2021

/// Bayer Pharmaceuticals /// Pipeline Overview October 30, 2025



Protein Therapeutics



Cell Therapy



Contrast Agent



Genetic Medicine



Radionuclide Therapy



Small Molecule



Pharmaceuticals – Pipeline Details Cardiovascular^{1,3} (as of October 30, 2025)


Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Finerenone (MR Antagonist)	Non-diabetic CKD (<i>FIND-CKD</i>)					NCT05047263	Q1 2026	Study ongoing
	CKD in Type 1 Diabetes (<i>FINE-ONE</i>)					NCT05901831	Q3 2025	Study ongoing
Vericiguat (sGC Stimulator)	Heart Failure (HFrEF) (<i>VICTOR²</i>)					NCT05093933	Q4 2024	Study completed
Asundexian (FXIa Inhibitor) (BAY 2433334)	2° Stroke Prevention (<i>OCEANIC-STROKE</i>)					NCT05686070	Q4 2025	Study ongoing
Congestive Heart Failure rAAV Gene Therapy (<i>AB-1002</i>)	Congestive Heart Failure (<i>GenePHIT</i>)					NCT05598333	Q4 2026	Study ongoing
Anti-a2AP (BAY 3018250)	Acute Ischemic Stroke; Pulmonary Embolism (<i>SIRIUS</i>)					NCT06149520	Q4 2025	Study ongoing
Nurandociguat (sGC Act. Oral) (BAY 3283142)	Chronic Kidney Disease (CKD)					NCT06522997	Q1 2026	Study ongoing
SEMA 3a (BAY 3401016)	Alport Syndrome					n/a	Q3 2025	Study ongoing
Dual FIIa/Xa Inhibitor (BAY 3389934)	Anti-coagulation					NCT06854640	Q1 2026	Study ongoing
GIRK4 Inhibitor (BAY 3670549)	Atrial fibrillation	Undisclosed				n/a	Q1 2026	Study ongoing

 Protein Therapeutics
  Cell Therapy
  Contrast Agent
  Genetic Medicine
  Radionuclide Therapy
  Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Conducted by Merck & Co ³ Including Precision Cardiovascular, Nephrology & Acute Care



Pharmaceuticals – Pipeline Details Neurol./Rare Dis.¹ (as of October 30, 2025)

Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Bemdaneprocel (Parkinson's Disease Cell Therapy)	Parkinson's Disease					NCT06944522	Q1 2027	Study ongoing
Parkinson's Disease rAAV Gene Therapy (AB-1005)	Parkinson's Disease					NCT06285643	Q4 2027	Study ongoing
Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)	Multiple System Atrophy					NCT04680065	Q3 2026	Study ongoing
Pompe Disease rAAV Gene Therapy (ACTUS-101)	Pompe Disease					NCT03533673	Q3 2022	Study ongoing
LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)	Limb-Girdle Muscular Dystrophy 2i					NCT05230459	Q4 2028	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



Pharmaceuticals – Pipeline Details Others¹ (as of October 30, 2025)

Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
GPR84 Antagonist (BAY 3178275)	Diabetic Neuropatic Pain					n/a	Q1 2024	Study completed
BAY 2701250	Pulmonary Hypertension					NCT06048120	Q2 2025	Study completed
Primary Photoreceptor Diseases Cell Therapy (BRT-OpCT-001)	Primary Photoreceptor Disease					NCT06789445	Q3 2029	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Phase II pilot study on sleep disturbances associated with menopause